Press Room - Sanofi US News
WEB2 days ago · Dr. Fox is a paid advisor to Sanofi for the HERCULES trial. Based on preliminary analysis of the HERCULES study, there was a slight increase in tolebrutinib-treated patients of some adverse events. Liver enzyme elevations (>3xULN) were observed in 4.1% of participants receiving tolebrutinib compared with 1.6% in the placebo group, a …
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB1 day ago · Sanofi's tolebrutinib drug delays progressive MS by 31% in trial. By Ludwig Burger. September 20, 2024 2:07 PM UTC Updated ago ... Reuters, the news and media division of Thomson Reuters, is the ...
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB1 day ago · Sanofi’s safety and tolerability analysis showed 4.1% of people on tolebrutinib had liver enzyme levels of at least three times the upper limit of normal, compared to 1.6% of the patients taking ...
Sanofi's tolebrutinib cuts MS progression by 31% in trial
WEB1 day ago · Sanofi revealed the top-line result from HERCULES a few weeks ago, noting that tolebrutinib is the only drug in the oral BTK inhibitor class to have shown an improvement in disability progression ...
Sanofi’s eyes approval after MS therapy slows disease progression …
WEB2 days ago · SNY. Sanofi is eyeing up global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS), The results from the ...
Sanofi's Tolebrutinib Delays Disability Progression In Patients …
WEB1 day ago · Friday, Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that ...
Tolebrutinib: New Sanofi’s Brain-Penetrant BTK Inhibitor | Sanofi
WEBFeb 23, 2022 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key immune mediators that may drive disease progression within the CNS.
Novel Agent First to Slow Disability in nrSPMS - Medscape
WEB1 day ago · September 20, 2024. 0. 0. COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis ...
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study ...
WEB1 day ago · Sanofi on Friday announced that its investigational BTK inhibitor tolebrutinib delayed the onset of disability progression by 31% in patients with non-relapsing secondary progressive multiple sclerosis.. The results come from the Phase III HERCULES study, a double-blinded randomized trial that compared daily oral tolebrutinib against placebo in terms of confirmed disease progression at six ...
Press Release: Tolebrutinib demonstrated a 31% delay in time ... - Sanofi
WEB2 days ago · *For participants receiving tolebrutinib. Houman Ashrafian, MD, PhD Head of Research & Development, Sanofi “With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by targeting underlying drivers of the disease. We look forward to discussing these results ...
Skip to content